Travoprost/timolol

Travoprost/timolol
Combination of
Travoprost	Prostaglandin analog
Timolol	Beta-blocker
Clinical data
Trade names	Duotrav
AHFS/Drugs.com	UK Drug Information
Pregnancy; category	AU:C;
Routes of; administration	Eye drops
ATC code	S01ED51 ( WHO );
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); EU:Rx-only;
Identifiers
CAS Number	874755-80-3 ;
KEGG	D09815 ;

Last updated October 04, 2025

Travoprost/timolol, sold under the brand name Duotrav among others, is a fixed-dose combination medication used for the treatment of glaucoma.^[4]^[5]^[6]^[7] It contains travoprost and timolol maleate.^[4]

It was authorized for medical use in the European Union in April 2006.^[4]

References

1 2 "Travoprost/timolol Product Information" (PDF). TGA eBS. Retrieved 23 May 2021.
↑ "DUOTRAV travoprost 0.004% and timolol 0.5% (as maleate) eye drop solution". Department of Health. Australian Government.
↑ "DuoTrav eye drops solution - Summary of Product Characteristics (SmPC)". (emc). 14 June 2018. Retrieved 30 October 2020.
1 2 3 4 "Duotrav EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 October 2020.
↑ Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL (2012). "Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis". PLOS ONE. 7 (9) e45079. Bibcode:2012PLoSO...745079C. doi: 10.1371/journal.pone.0045079 . PMC 3441590 . PMID 23028770.
↑ Konstas AG, Quaranta L, Realini T (April 2012). "Overview of the [corrected] travoprost /timolol BAK-free fixed combination". Expert Opinion on Pharmacotherapy. 13 (5): 757–66. doi:10.1517/14656566.2012.662485. PMID 22360540. S2CID 24160793.
↑ Denis P (February 2011). "Travoprost/timolol fixed combination in the management of open-angle glaucoma: a clinical review". Expert Opinion on Pharmacotherapy. 12 (3): 463–71. doi:10.1517/14656566.2011.551007. PMID 21254951. S2CID 46258207.

External links

"Timolol maleate mixture with Travoprost". Drug Information Portal. U.S. National Library of Medicine.^{[ dead link ]}

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[DuoTrav_TGA_label-1] 1 2 "Travoprost/timolol Product Information" (PDF). TGA eBS. Retrieved 23 May 2021.

[2] "DUOTRAV travoprost 0.004% and timolol 0.5% (as maleate) eye drop solution". Department of Health. Australian Government.

[3] "DuoTrav eye drops solution - Summary of Product Characteristics (SmPC)". (emc). 14 June 2018. Retrieved 30 October 2020.

[Duotrav_EPAR-4] 1 2 3 4 "Duotrav EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 October 2020.

[Cheng_2012-5] Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL (2012). "Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis". PLOS ONE. 7 (9) e45079. Bibcode:2012PLoSO...745079C. doi: 10.1371/journal.pone.0045079 . PMC 3441590 . PMID 23028770.

[Konstas_2012-6] Konstas AG, Quaranta L, Realini T (April 2012). "Overview of the [corrected] travoprost /timolol BAK-free fixed combination". Expert Opinion on Pharmacotherapy. 13 (5): 757–66. doi:10.1517/14656566.2012.662485. PMID 22360540. S2CID 24160793.

[Denis_2011-7] Denis P (February 2011). "Travoprost/timolol fixed combination in the management of open-angle glaucoma: a clinical review". Expert Opinion on Pharmacotherapy. 12 (3): 463–71. doi:10.1517/14656566.2011.551007. PMID 21254951. S2CID 46258207.

[1]

[2]

[3]

[4]

[5]

[6]

[7]